Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Survodutide activates GLP-1 and glucagon . The GLP-1 component contributes the incretin effects shared with semaglutide / tirzepatide (insulin release, appetite suppression, gastric emptying delay). The glucagon component contributes additional energy-expenditure and hepatic-fat effects in research models.
02
Research applications
- Obesity clinical research (Phase II + III)
- MASH / NASH clinical research
- Dual- incretin pharmacology
- Glucagon- metabolic research
Evidence at a glance
What's behind this profile
3 citations · 2022–2024
- Human
- 2
- Other
- 1
Studies in human volunteers or patients (incl. early-phase trials).
Studies that did not match the categories above.
Publication years
- 22
- 23
- 24
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 2 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
2022
Zimmermann T et al. · Molecular Metabolism
- Model
- Preclinical pharmacology characterisation in rodent models
- Sample
- Not reported in abstract
Reported the discovery and characterisation of BI 456906 (survodutide), showing dual GCGR/GLP-1R agonism with greater body-weight reduction than semaglutide monotherapy in rodent obesity models.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
2024
le Roux CW et al. · The Lancet Diabetes & Endocrinology
- Model
- Phase 2 dose-finding double-blind RCT in adults with obesity
- Sample
- n=386
Survodutide was associated with dose-dependent body-weight reductions up to 14.9% over 46 weeks; gastrointestinal events were the most common adverse events.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024
Sanyal AJ et al. · New England Journal of Medicine
- Model
- Phase 2 double-blind RCT in adults with biopsy-confirmed MASH and significant fibrosis
- Sample
- n=293
Survodutide was associated with higher rates of MASH improvement without worsening fibrosis versus placebo at 48 weeks.
Evidence caveats
- Survodutide is investigational. Phase III trials are ongoing; no Phase III outcome data are published at the time of writing.
- All efficacy data are from Phase II trials. Long-term safety, cardiovascular outcomes, and head-to-head comparison with tirzepatide / retatrutide have not been established.
04
Storage and handling
Trial material follows the clinical trial protocol cold-chain. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Investigational compound — use is restricted to authorised clinical trials and research settings.
- Trial product cold-chain follows the clinical trial protocol.
- Maintain full batch and supplier traceability.